A carregar...
Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway
Non-small cell lung cancer (NSCLC) accounts for >80% of all lung cancer cases, which are the leading cause of cancer-related mortality worldwide. The clinical efficacy of available therapies for NSCLC is often limited due to the development of resistance to anticancer drugs, particularly to cispl...
Na minha lista:
| Publicado no: | Oncol Rep |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6072289/ https://ncbi.nlm.nih.gov/pubmed/29901163 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2018.6486 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|